secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001213900-24-015295
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals sponsors pre-clinical study of tafenoquine against Candida auris with Monash University
--------------------------------------------------------------------------------

- Animal studies will test tafenoquine efficacy against Candida spp, including drug-resistant Candida auris.
- Monash University conducts studies; experiments start May 2024, completion by Nov 30, 2024.
- Company to pay Monash $90,167 AUD on April 1, 2024 and $90,167 AUD on service completion.
- Tafenoquine is FDA-approved for malaria prophylaxis; its antifungal mode of action is differentiated from standard care.
- Results expected by end of 2024; earlier in vitro data showed broad-spectrum antifungal activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024015295/0001213900-24-015295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024015295/ea0200322-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-015295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer